Serum Uric Acid in Chronic Kidney Disease as a Marker of Risk or a Modifiable Driver of Progression: A Systematic Review
Abstract
Serum uric acid has been investigated as a marker and potential therapeutic target in chronic kidney disease (CKD), but its clinical significance remains uncertain because hyperuricemia may represent both a consequence of impaired renal clearance and a possible contributor to kidney injury. This systematic review evaluated associations between serum uric acid status, urate-lowering interventions, and renal outcomes in adults with CKD or hyperuricemia-associated kidney disease. PubMed/MEDLINE, Scopus, and Web of Science were searched for studies published from January 1, 2019, to April 1, 2026, with supplementary citation searching conducted during revision. Seven studies met the eligibility criteria, including randomized controlled trials, trial sub-analyses, exploratory analyses, and post-hoc analyses. Narrative synthesis was performed because clinical and methodological heterogeneity precluded meta-analysis. Higher baseline or sustained serum uric acid was associated with less favorable renal trajectories in selected populations, particularly when assessed longitudinally or as average exposure during follow-up. However, pharmacologic urate reduction did not consistently improve albuminuria, proteinuria, measured glomerular filtration rate, or estimated glomerular filtration rate outcomes. In Preventing Early Renal Loss in Diabetes (PERL), the between-group difference in measured glomerular filtration rate with allopurinol versus placebo was 0.001 mL/min/1.73 m² (95%…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.